| |
KOMISJA NADZORU FINANSOWEGO |
|
| |
|
|
Raport bieżący nr |
19 |
/ |
2021 |
|
|
|
| |
Data sporządzenia: |
2021-12-01 |
|
|
|
|
|
|
|
|
|
| |
Skrócona nazwa emitenta |
|
|
|
|
|
|
|
|
|
| |
MILESTONE MEDICAL |
|
| |
Temat |
|
|
|
|
|
|
|
|
|
|
| |
Adoption of CompuFlo Epidural Instrument for Pain Management by Dr. Miguel de la Garza,
President of the Florida Society of Interventional Pain Physicians and Renowned Physician
at Surgery Partners
|
|
| |
Podstawa prawna |
|
|
|
|
|
|
|
|
| |
Art. 17 ust. 1 MAR - informacje poufne.
|
|
| |
Treść raportu: |
|
|
|
|
|
|
|
|
|
| |
The Board of Directors of Milestone Medical Inc. _WAR: MMD, "the Company", "the Issuer"_,
today announced that Dr. Miguel de la Garza has begun incorporating the CompuFlo Epidural
instrument into his practice for pain management, following approval by Surgery Partners,
one of the largest and growing surgical services business in the country. Dr. de la
Garza plans to utilize the CompuFlo Epidural instrument for both surgical cases and
office based procedures to safely and quickly access the epidural space.
Dr. de la Garza, a recognized expert in pain management, is the current president
of the Florida Society of Interventional Pain Physicians, which is one of the largest
pain societies in the United States, representing 400 interventional pain management
specialists in the state of Florida. He is a partner at Comprehensive Pain Management
Partners in Tampa, Florida, and performs his clinical pain management procedures at
Surgery Partners. Founded in 2004, Surgery Partners has over 4,000 affiliated physicians,
and more than 180 locations in 31 states, including ambulatory surgery centers, surgical
hospitals, multi-specialty physician practices and urgent care facilities.
The Board of Directors of the Company appreciates the support of Dr. Miguel de la
Garza who is a leader in the field of pain management. The Board of Directors of the
Company is also pleased to announce that Surgery Partners has approved the CompuFlo
Epidural instrument for use across their network in pain management. This latest agreement
marks a major step in our goal of expanding the addressable market for CompuFlo Epidural
instrument beyond labor and delivery. In the opinion of the Board of Directors of
the Company the CompuFlo Epidural instrument has the potential to capture a significant
share of this market given its safety, reduced risk of complications and cost savings.
|
|
|
RB_ASO: Adoption of CompuFlo Epidural Instrument for Pain Management by Dr. Miguel de la Garza,
President of the Florida Society of Interventional Pain Physicians and Renowned Physician
at Surgery Partners
